Novel furosemide cocrystals and selection of high solubility drug forms

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 664-680

  Goud, N Rajesh ^a   Gangavaram, Swarupa ^a   Suresh, Kuthuru ^a   Pal, Sharmistha ^b   Manjunatha, Sulur G ^b   Nambiar, Sudhir ^b   Nangia, Ashwini ^a  

^a UNIVERSITY OF HYDERABAD   (India)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bioavailability; Co crystal; Crystallography; Dissolution; Furosemide; Solid dosage form; Solubility; Stability; Thermal analysis; X ray diffractometry

Indexed keywords

ADENINE; AMINOBENZOIC ACID; CAFFEINE; CYTOSINE; FUROSEMIDE; ISONICOTINAMIDE; NICOTINAMIDE; UREA;

ARTICLE; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; HYDROGEN BOND; LOW TEMPERATURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; POLARIZATION; RAMAN SPECTROMETRY; SOLID; STOICHIOMETRY; X RAY DIFFRACTION;

EID: 84455169482     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22805     Document Type: Article

References (68)

1. Qiu Y, Chen Y, Zhang GGZ., Eds. 2009. Developing solid oral dosage forms: Pharmaceutical theory and practice, 1st ed. New York: Academic Press.
2. Thayer AM. 2010. Finding solutions. Chem Eng News 88:13-18.
3. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. Theoretical basis for a biopharmaceutical drug classification: correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
4. Dahan A, Miller JM, Amidon GL. 2009. Prediction of solubility and permeability class membership: Provisional BCS classification of world's top oral drugs. AAPS J 11:740-746.
5. Friedman PA, Berndt WO. 1997. In Modern pharmacology with clinical applications; Craig CR, Stitzel RE, Eds. 5th ed. Boston, MA: Little Brown and Company, pp 239-255.
6. Khan MG. 2006. Encyclopedia of heart diseases. 15th ed. New York: Elsevier, pp 486.
7. Blagden N, de Matas M, Gavan PT, York P. 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Del Rev 59:617-630.
8. Shan N, Zaworotko MJ. 2008. The role of cocrystals in pharmaceutical science. Drug Discov Today 13:440-446.
9. Doherty C, York P. 1988. Furosemide crystal forms: Solid state and physicochemical analyses. Int J Pharm 47:141-155.
10. Matsuda Y, Tatsumi E. 1990. Physicochemical characterization of furosemide modifications. Int J Pharm 60:11-26.
11. Ge M, Liu G, Ma S, Wang W. 2009. Polymorphic forms of furosemide characterized by THz time domain spectroscopy. Bull Korean Chem Soc 30:2265-2268.
12. Karami S, Li Y, Hughes DS, Hursthouse MB, Russell AE, Threlfall TL, Claybourn M, Roberts R. 2006. Further errors in polymorph identification: Furosemide and finasteride. Acta Crystallogr B 62:689-691.
13. Babu NJ, Cherukuvada S, Thakuria R, Nangia A. 2010. Conformational and synthon polymorphism in furosemide (Lasix). Cryst Growth Des 10:1979-1989.
14. Ai H, Jones SA, deVilliers MM, Lvov YM. 2003. Nano encapsulation of furosemide microcrystals for controlled drug release. J Control Release 86:59-68.
15. Matsuda Y, Otsuka M, Onoe M, Tatsumi E. 1992. Amorphism and Physicochemical stability of spray-dried frusemide. J Pharm Pharmacol 44:627-633.
16. Shin SC, Oh IJ, Lee YB, Choi HK, Choi JS. 1998. Enhanced dissolution of furosemide by coprecipitating or cogrinding with crospovidone. Int J Pharm 175:17-24.
17. Shin SC, Kim J. 2003. Physicochemical characterization of solid dispersion of furosemide with TPGS. Int J Pharm 251:79-84.
18. Özdemir N, Ordu S. 1998. Improvement of dissolution properties of furosemide by complexation with β-cyclodextrin. Drug Dev Ind Pharm 24:19-25.
19. Kreaz RMA, Abu-Eida EY, Eros I, Kata M. 1999. Freeze dried complexes of furosemide with β-cyclodextrin derivatives. J Incl Phenom Macrocycl Chem 34:39-48.
20. Wongmekiat A, Yoshimatsu S, Tozuka Y, Moribe K, Yamamoto K. 2006. Investigation of drug nanoparticle formation by cogrinding with cyclodextrins: studies for Indomethacin, Furosemide and Naproxen. J Incl Phenom Macrocycl Chem 56:29-32.
21. Yang W, de Villiers MM. 2004. Aqueous solubilization of furosemide by supramolecular complexation with 4-sulphonic calix[n]arenes. J Pharm Pharmacol 56:703-708.
22. Zvonar A, Berginc K, Kristl A, Gašperlin M. 2010. Microencapsulation of self-microemulsifying system: Improving solubility and permeability of furosemide. Int J Pharm 388:151-158.
23. Latere Dwan'lsa JP, Rouxhet L, Brewster ME, Préat V, Ariën A. 2008. Spontaneously self-assembled micelles from poly(ethylene glycol)-b-poly(ε-caprolactone-co-trimethylene carbonate) for drug solubilization. Pharmazie 63:235-240.
24. Shaji J, Jadhav D. 2010. Newer approaches to self emulsifying drug delivery system. Int J Pharm Pharm Sci 2:37-42.
25. Otsuka M, Onoe M, Matsuda M. 1993. Hygroscopic stability and dissolution properties of spray-dried solid dispersions of furosemide with eudragit. J Pharm Sci 82:32-38.
26. Brittain HG. 2010. Cocrystal systems of pharmaceutical interest: 2007-2008. Profiles Drug Substances, Excipients Related Methodology 35:373-390.
27. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ. 2006. Pharmaceutical Co-Crystals. J Pharm Sci 95:499-516.
28. Friščić T, Jones W. 2010. Benefits of cocrystallisation in pharmaceutical materials science: an update. J Pharm Pharmacol 62:1547-1559.
29. Desiraju GR. 1995. Supramolecular synthons in crystal engineering-A new organic synthesis. Angew Chem, Int Ed Engl 34:2311-2327.
30. Desiraju GR. 2007. Crystal Engineering: A holistic view. Angew Chem, Int Ed 46: 8342-8356.
31. Bhogala BR, Nangia A. 2003. Cocrystals of 1, 3, 5-cyclohexanetricarboxylic acid with 4, 4' bipyridine homologues: Acid-pyridine hydrogen bonding in neutral and ionic complexes. Cryst Growth Des 3:547-554.
32. Caira MR. 2007. Sulfa drugs as model cocrystal formers. Mol Pharmaceutics 4:310-316.
33. 2-receptor antagonists. Five 3-[2-(diaminomethyleneamino)-4-thiazolylmethylthio] propionamidine and amide derivatives. Acta Crystallogr B 45:505-512.
34. Goud NR, Babu NJ, Nangia A. 2011. Sulfonamide-pyridine-N-oxide cocrystals. Cryst Growth Des 11:1930-1939.
35. Pellegata RL. 1990. Furosemide salts. Patent US 5182300.
36. Carda-Broch S, Esteve-Romero J, Garcia-Alvarez-Coque MC. 2000. Furosemide assay in pharmaceuticals by micellar liquid chromatography: Study of the stability of the drug. J Pharm Biomed Anal 23:803-817.
37. Trask AV. 2007. An overview of Pharmaceutical cocrystals as Intellectual property. Mol Pharmaceutics 4:301-309.
38. Babu NJ, Nangia A. 2011. Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals. Cryst Growth Des 11: 2662-2679.
39. GRAS chemical list. Accessed at.
40. Childs SL, Stahly GP, Park A. 2007. The salt-cocrystal continuum: the influence of crystal structure on ionization state. Mol Pharmaceutics 4:323-328.
41. Vogt FG, Clawson JS, Strohmeier M, Edwards AJ, Pham TN, Watson SA. 2009. Solid state NMR analysis of organic cocrystals and complexes. Cryst Growth Des 9:921-937.
42. Stevens JS, Byard SJ, Schroeder SLM. 2010. Salt or co-crystal? Determination of protonation state by x-ray photoelectron spectroscopy (XPS). J Pharm Sci 99:4453-4457.
43. Shan N, Toda F, Jones W. 2002. Mechanochemistry and co-crystal formation: Effect of solvent on reaction kinetics. Chem Commun 20:2372-2373.
44. Beyers H, Malan SF, van der Watt JG, de Villiers MM. 2000. Structure-solubility relationship and thermal decomposition of furosemide. Drug Dev Ind Pharm 26:1077-1083.
45. 15N NMR spectroscopy. J Am Chem Soc 128:8199-8210.
46. Bernstein J, Davis RE, Shimoni L, Chang NL. 1995. Patterns in hydrogen bonding: Functionality and graph set analysis in crystals. Angew Chem, Int Ed Engl 34:1555-1573.
47. Chieng N, Rades T, Aaltonen J. 2011. An overview of recent studies on the analysis of pharmaceutical polymorphs. J Pharm Biomed Anal 55:618-644.
48. Trask AV, Jones W. 2005. Crystal Engineering of organic cocrystals by the solid-state grinding approach. Top Curr Chem 254:41-70.
49. Schultheiss N, Newman A. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 9:2950-2967.
50. Li J, Bourne SA, Caira MR. 2011. New polymorphs of isonicotinamide and nicotinamide. Chem Commun 47:1530-1532.
51. 2H, n = 7-9. CrystEngComm 13:4188-4195.
52. Vishweshwar P, Nangia A, Lynch VM. 2003. Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons and melting point alternation. Cryst Growth Des 3:783-790.
53. Cherukuvada S, Babu NJ, Nangia A. Nitrofurantoin-p-aminobenzoic acid cocrystal: Hydration stability and dissolution rate studies. J Pharm Sci 100:3233-3244.
54. Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic and fumaric acids. J Am Chem Soc 126:13335-13342.
55. Fahr A, Liu X. 2007. Drug-delivery strategies for poorly water soluble drugs. Expert Opin Drug Deliv 4:403-416.
56. Cheney ML, Shan N, Healey ER, Hanna M, Wojtas L, Zaworotko MJ, Sasa V, Song S, Sanchez-Ramos JR. 2010. Effects of crystal form on solubility and pharmacokinetics: a crystal engineering case study of lamotrigine. Cryst Growth Des 10:394-405.
57. Good D, Rodríguez-Hornedo N. 2009. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des 9:2252-2264.
58. Bethune SJ, Huang N, Jayasankar A, Rodríguez-Hornedo N. 2009. Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility. Cryst Growth Des 9:3976-3988.
59. Jayasankar A, Reddy LS, Bethune SJ, Rodríguez-Hornedo N. 2009. Role of cocrystal and solution chemistry on the formation and stability of cocrystals with different stoichiometry. Cryst Growth Des 9:889-897.
60. Guo K, Sadiq G, Seaton C, Davey R, Yin Q. 2010. Co-crystallization in the caffeine/maleic acid system: Lessons from phase equilibria. Cryst Growth Des 10:268-273.
61. Powder Cell, a program for structure visualization, powder pattern calculation and profile fitting. Accessed at.
62. Cambridge Crystallographic Data Center, Cambridge Structural Database, version 5.32, November 2010, August 2011 update Available at.
63. SAINT-Plus, version 6.45. 2003. Madison, WI: Bruker AXS Inc.
64. Sheldrick GM. 1997. SADABS, program for empirical absorption correction of area detector data. Göttingen, Germany: University of Göttingen.
65. Sheldrick GM. 1997. SHELXS-97 and SHELXL-97, Göttingen, Germany: University of Göttingen.
66. Spek AL. 2002. PLATON, a multipurpose crystallographic tool. Utrecht, The Netherlands: Utrecht University.
67. Barbour LJ. 1999. X-Seed, graphical interface to SHELX-97 and POV-Ray. Columbia, MO: University of Missouri-Columbia.
68. Higuchi T, Connors KA. 1965. Phase-solubility techniques. Adv Anal Chem Instrum 4:117-212.